Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Trading Arrangement: Trading Arrangement [Axis] Options outstanding, Weighted average remaining contractual term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted-Average Remaining Contractual Term Maximum Maximum [Member] Statistical Measurement [Domain] Statistical Measurement [Domain] Short-Term Debt, Type [Axis] Short-Term Debt, Type [Axis] Title of 12(b) Security Title of 12(b) Security Subsequent Event Subsequent Event [Member] Document Fiscal Year Focus Document Fiscal Year Focus Investments Increase (Decrease) of Restricted Investments Adjustment to Compensation, Amount Adjustment to Compensation Amount Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Common stock, $0.00001 par value, 100,000,000 shares authorized; 18,541,651 and 11,418,183 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively. Common Stock, Value, Issued Departed Employee Departed Employee [Member] Departed Employee Line of Credit Line of Credit [Member] Entity Ex Transition Period Entity Ex Transition Period Restatement Determination Date Restatement Determination Date Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] License initiation fee License Initiation Fee License initiation fee. Derivative Instrument [Axis] Derivative Instrument [Axis] Investors Investors [Member] Investors [Member] Issuance of common stock upon vesting of restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Vested, Weighted-Average Exercise Price (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Amendment Flag Amendment Flag Current liabilities Liabilities, Current [Abstract] Project [Axis] Project [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding From 2023 through 2027 From 2023 through 2027 [Member] From 2023 through 2027 [Member] Class of Warrant or Right [Table] Class of Warrant or Right [Table] Issuance of common stock pursuant to warrant exercises (in shares) Stock issued during period, shares, other (in shares) Stock Issued During Period, Shares, Other $2.00 - $2.66 $2.00 - $2.66 [Member] $2.00 - $2.66 [Member] Investments Investment [Text Block] Material Agreements License And Royalty Agreement Disclosure [Text Block] License and Royalty Agreement Disclosure [Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Entity Address, State or Province Entity Address, State or Province Number of share granted (in share) Granted (in share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross PEO Total Compensation Amount PEO Total Compensation Amount Common stock, par or stated value per share (in dollars per share) Common stock, par or stated value per share (in dollars per share) Common Stock, Par or Stated Value Per Share Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Weighted average number of shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Long-term investments Long-Term Investments Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Total current liabilities Liabilities, Current Accrued portion of annual license fees Accrued Portion of Annual License Fees Accrued portion of annual license fees. Tradeable Warrants Tradeable Warrants [Member] Tradeable Warrants [Member] Common Stock $0.00001 Par Value Per Share Common Stock $0.00001 Par Value Per Share [Member] Common Stock $0.00001 par value per share [Member] Deferred revenue Increase (Decrease) in Deferred Revenue Short-Term Debt, Type [Domain] Short-Term Debt, Type [Domain] $6.51 - $7.80 $6.51 - $7.80 [Member] $6.51 - $7.80 [Member] Entity Address, City or Town Entity Address, City or Town Granted (in share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Title and Position [Domain] Title and Position [Domain] Document Information [Line Items] Document Information [Line Items] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Class of Stock [Axis] Class of Stock [Axis] Material Agreements Material Agreements [Abstract] Material Agreements Royalty expense Royalty Expense Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Payments for royalties Payments for Royalties JHU-APL Technology License JHU - APL Technology License Agreement [Member] JHU - APL Technology License Agreement [Member] Other income (expense), net Nonoperating Income (Expense) [Abstract] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Warrant issuance percentage Warrant Issuance Percentage Percentage of warrant issued. Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] License payments License Payments License payments. License fee payment made after IPO License Fee Payment Made After IPO Payments for license fees after IPO. Exercise Price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Document Period End Date Document Period End Date Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Net cash used in investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Stockholders’ Equity Equity [Text Block] Investments, All Other Investments [Abstract] Investments, All Other Investments [Abstract] Security Exchange Name Security Exchange Name Share granted, weighted average exercise prices per share (in dollars per share) Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Payments for other fees Payments for Other Fees Entity Shell Company Entity Shell Company Number of patent applications Licensing Arrangement, Number of Patent Applications Licensing Arrangement, Number of Patent Applications Share-based compensation arrangement by share-based payment award, number of shares authorized (in share) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized MaterialAgreements [Line Items] MaterialAgreements [Line Items] MaterialAgreements Percentage of commission on gross sales price Percentage of commission on gross sales price Percentage of commission on gross sale price. Name Outstanding Recovery, Individual Name Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Accrued revenue Increase (Decrease) in Accrued Revenue, Current Increase (Decrease) in Accrued Revenue, Current Total liabilities Liabilities Trading Symbol Trading Symbol Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Share-based payment arrangement, nonvested award, option, cost not yet recognized, amount Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Lieber Institute for Brain Development Partnership Lieber Institute for Brain Development Partnership [Member] Lieber Institute for Brain Development Partnership Company Selected Measure Name Company Selected Measure Name Sale of Stock [Domain] Sale of Stock [Domain] Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash Restrictions on Cash and Cash Equivalents [Table Text Block] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Award Date [Axis] Award Date [Axis] Supplemental disclosures of noncash investing and financing activities Noncash Investing and Financing Items [Abstract] Schedule of Outstanding Warrants Schedule of Outstanding Warrants [Table Text Block] Schedule of Outstanding Warrants [Table Text Block] Credit Facility [Domain] Credit Facility [Domain] Cash flows from operating activities: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Johns Hopkins University - Mebendazole License Agreement Johns Hopkins University - Mebendazole License Agreement [Member] Johns Hopkins University - Mebendazole License Agreement [Member] Compensation Amount Outstanding Recovery Compensation Amount Individual: Individual [Axis] Warrant Warrant [Member] Weighted average number of shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Entity Emerging Growth Company Entity Emerging Growth Company Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Number of patients enrolled Clinical Trial, Number of Patients Enrolled Clinical Trial, Number of Patients Enrolled Underlying Security Market Price Change Underlying Security Market Price Change, Percent 2022 2022 [Member] 2022 [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Award Date [Domain] Award Date [Domain] Gross profit Gross Profit Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Two year overall survival rate Clinical Trial, Two Year Overall Survival Rate, Percentage Clinical Trial, Two Year Overall Survival Rate, Percentage Cost of revenue Cost of Revenue [Abstract] Award Timing Predetermined Award Timing Predetermined [Flag] Restricted cash Restricted Cash, Current Project [Domain] Project [Domain] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] $3.36 - $4.16 $3.36 - $4.16 [Member] $3.36 - $4.16 [Member] Outstanding, beginning balance (in dollars per share) Outstanding, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value All Executive Categories All Executive Categories [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Johns Hopkins University - Prodrug License Agreement Johns Hopkins University - Prodrug License Agreement [Member] Johns Hopkins University - Prodrug License Agreement [Member] Preferred stock, par or stated value per share (in dollars per share) Preferred Stock, Par or Stated Value Per Share Collaborative arrangement termination cure period Licensing Arrangement, Cure Period for Material Breach Licensing Arrangement, Cure Period for Material Breach Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Initial maximum number of shares authorized under equity incentive plan (in share) Initial Maximum Number of Shares Authorized Under Equity Incentive Plan Share based compensation arrangement by share based payment award number of shares authorized under equity plan. Depreciation Depreciation Plan Name [Domain] Plan Name [Domain] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Outstanding, beginning balance (in dollars per share) Outstanding, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Legal fees Legal Fees June 2026 June 2026 [Member] June 2026 [Member] Number of pre-funded warrants included in EPS calculation (in share) Number of Pre-Funded Warrants Included in EPS Calculation Antidilutive securities included from computation of earnings per share amount. Risk-free interest rate , Maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Debt Disclosure [Abstract] Debt Disclosure [Abstract] Finite-lived patents, gross Finite-Lived Patents, Gross Issuance of common stock pursuant to warrant exercises Stock Issued During Period, Value, Other Minimum Minimum [Member] Expiration Date Trading Arrangement Expiration Date Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Options outstanding, Weighted average remaining contractual term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted-Average Remaining Contractual Term Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Other Parties Other Parties [Member] Other Parties [Member] Series A Convertible Preferred Stock Series A Convertible Preferred Stock [Member] Series A Convertible Preferred Stock [Member] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Proceeds from issuance of common stock, net of issuance costs Proceeds from Issuance of Common Stock Common stock, shares authorized (in shares) Common Stock, Shares Authorized Sale of stock, number of shares issued in transaction (in shares) Sale of Stock, Number of Shares Issued in Transaction MaterialAgreementsTable [Table] MaterialAgreementsTable [Table] MaterialAgreementsTable [Table] Annual license fee Annual license fee Annual license fee. Exercise Price Award Exercise Price Cash flows from investing activities: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Share repurchase program, authorized, amount Share Repurchase Program, Authorized, Amount Document Quarterly Report Document Quarterly Report Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] July 2023 July 2023 [Member] July 2023 [Member] Measurement period Clinical Trial, Measurement Period Clinical Trial, Measurement Period Notes Payable Debt Disclosure [Text Block] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Equity Component [Domain] Equity Component [Domain] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Sublicense percentage Sublicense Percentage Percentage of sublicense. Sale of stock, consideration received on transaction Sale of Stock, Consideration Received on Transaction Adoption Date Trading Arrangement Adoption Date Share based compensation price minimum percentage of fair market value Share-Based Compensation Arrangement by Share-Based Payment Award, Exercise Price, Minimum Percentage of Fair Market Value Share Based Compensation Arrangement By Share Based Payment Award Options Exercise Price Minimum Percentage Of Fair Market Value Proceeds from issuance or sale of equity Proceeds from Issuance or Sale of Equity Counterparty Name [Domain] Counterparty Name [Domain] Total stockholders’ equity Beginning balance Ending balance Stockholders’ equity Equity, Attributable to Parent Value of equity securities received from customer Value of Equity Securities Received from Customer Proceeds from equity securities received. Total other income (expense), net Nonoperating Income (Expense) Proceeds from short term insurance financing Proceeds from Other Short-Term Debt Sublicense percentage Sublicense percentage [Default Label] Increase decrease in sublicense percentage. Assets Assets [Abstract] Title Trading Arrangement, Individual Title Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Accounting Policies [Abstract] Accounting Policies [Abstract] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Insider Trading Policies and Procedures [Line Items] Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Vested at June 30, 2026 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract] Prepaid expenses and other assets Prepaid Expense and Other Assets, Current Share-based compensation arrangement by share-based payment award, percentage of outstanding stock maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum Linco ln Park Capital Fund LLC Linco ln Park Capital Fund LLC [Member] Linco ln Park Capital Fund LLC [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Antidilutive securities excluded from computation of earnings per share, amount (in share) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Number of operating segments Number of Operating Segments Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Entity Central Index Key Entity Central Index Key Notes payable, current Notes Payable, Current All Adjustments to Compensation All Adjustments to Compensation [Member] Expenses incurred noncash expenses Expenses Incurred, Noncash Expenses Expenses incurred noncash expenses. Equity [Abstract] Equity [Abstract] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Debt instrument, convertible, compliance period Debt Instrument, Convertible, Compliance Period Debt Instrument, Convertible, Compliance Period Income Statement [Abstract] Income Statement [Abstract] Stockholders’ equity Equity, Attributable to Parent [Abstract] Document Transition Report Document Transition Report Investment, Name [Axis] Investment, Name [Axis] Operating expenses Operating Expenses [Abstract] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Debt instrument, interest rate, increase (decrease) Debt Instrument, Interest Rate, Increase (Decrease) Schedule of Black Scholes Option Pricing Model Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] City Area Code City Area Code 2027 2027 [Member] 2027 [Member] Percentage of royalty on net sales Percentage of Royalty on Net Sales Percentage of royalty on net sales. Document Information [Table] Document Information [Table] All Individuals All Individuals [Member] Subsequent Events Subsequent Events [Text Block] 0.0007 $0.0007 [Member] $0.0007 [Member] Name Forgone Recovery, Individual Name Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Weighted-Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Statement [Line Items] Statement [Line Items] Total assets Assets Entity [Domain] Entity [Domain] Share-based compensation arrangement by share-based payment award, accelerated vesting, number (in share) Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number Weighted-Average Remaining Contractual Term (Years) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Interest expense Interest Expense, Nonoperating Issuance of common stock, net of issuance costs (in shares) Stock issued during period shares new issues (in share) Stock Issued During Period, Shares, New Issues PEO PEO [Member] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Share-based payment arrangement, expense Share-Based Payment Arrangement, Expense Preferred stock, convertible, conversion ratio Preferred Stock, Convertible, Conversion Ratio Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Exercised (in share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Investments Investments Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Company Financings Company Financings [Member] Company Financings [Member] Contract with customer, liability, revenue recognized Contract with Customer, Liability, Revenue Recognized Subsequent Event Type [Domain] Subsequent Event Type [Domain] Accumulated Deficit Retained Earnings [Member] 2024 and Beyond 2024 and Beyond [Member] 2024 and Beyond [Member] Total operating expenses Operating Expenses Four year overall survival rate Clinical Trial, Four Year Overall Survival Rate, Percentage Clinical Trial, Four Year Overall Survival Rate, Percentage Forfeited / canceled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Series A Preferred Stock Series A Preferred Stock [Member] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Forfeited / canceled (in share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Common stock, shares, outstanding (in shares) Common Stock, Shares, Outstanding Award Timing Disclosures [Line Items] Net loss per common share attributable to common stockholders - diluted (in dollars per share) Earnings Per Share, Diluted Entity Current Reporting Status Entity Current Reporting Status Net cash provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Expected volatility , Maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Total Shareholder Return Amount Total Shareholder Return Amount Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Research and development Research and Development Expense Adjustments to reconcile net loss to net cash used in operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Agreement term Contract With Customer, Term Contract With Customer, Term IPO IPO [Member] Cash flows from financing activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Collaboration revenue Revenue from Contract with Customer, Excluding Assessed Tax Property and equipment, net Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Annual license maintenance fees Annual License Maintenance Fees License maintenance fees. Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Underlying Securities Award Underlying Securities Amount Revenue Revenue from Contract with Customer [Text Block] Issuance of common stock, net of issuance costs Stock issued during period value new issues Stock Issued During Period, Value, New Issues Forfeited / canceled (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Cash Cash Preferred Stock Preferred Stock [Member] Debt instrument, periodic payment, principal Debt Instrument, Periodic Payment, Principal Risk-free interest rate , Minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Reclass of commitment shares against stock issuance proceeds Stock Issued Title and Position [Axis] Title and Position [Axis] Sale of Stock [Axis] Sale of Stock [Axis] Weighted-Average Remaining Contractual Term (Years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] All Trading Arrangements All Trading Arrangements [Member] Other Performance Measure, Amount Other Performance Measure, Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Loss from operations Operating Income (Loss) 2030 2030 [Member] 2030 [Member] Debt instrument, number of monthly installments Debt Instrument, Number Of Monthly Installments Debt Instrument, Number Of Monthly Installments Current Fiscal Year End Date Current Fiscal Year End Date Proceeds from issuance of debt Proceeds from Issuance of Debt Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Equity Option Equity Option [Member] Entity File Number Entity File Number Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Stock-based compensation Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Schedule of Stock Options Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Weighted-Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Feasibility Agreement Feasibility Agreement [Member] Feasibility Agreement Common stock, shares, issued (in shares) Common Stock, Shares, Issued Measure: Measure [Axis] Accrued royalties, current Accrued Royalties, Current Equity Components [Axis] Equity Components [Axis] New License Agreement New License Agreement [Member] New License Agreement [Member] Class of Stock [Line Items] Class of Stock [Line Items] Entity Interactive Data Current Entity Interactive Data Current Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Entity Small Business Entity Small Business Termination Date Trading Arrangement Termination Date 8.125 $8.125 [Member] $8.125 [Member] Subsequent Events [Abstract] Subsequent Events [Abstract] Research and development period Collaborative Arrangement, Research and Development Period Collaborative Arrangement, Research and Development Period Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Reverse stock split conversion ratio Stockholders' Equity Note, Stock Split, Conversion Ratio MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Short term insurance financing Other Liabilities, Current Document Type Document Type Accrued expenses Accrued Liabilities, Current Fair Value as of Grant Date Award Grant Date Fair Value Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Arrangement Duration Trading Arrangement Duration Statement of Stockholders' Equity [Abstract] Local Phone Number Local Phone Number Number of issued patents Licensing Arrangement, Number of Patents Issued Licensing Arrangement, Number of Patents Issued Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Registrant Name Entity Registrant Name Accrued royalties Accrued Royalties Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] 2026 2026 [Member] 2026 [Member] Vested, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value 1.22 $1.22 [Member] $1.22 [Member] Total revenue Revenues Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Executive Category: Executive Category [Axis] Uncollected proceeds from stock issuance Uncollected Proceeds from Stock Issuance [Member] Uncollected Proceeds from Stock Issuance [Member] Schedule of Nonvested Restricted Stock Units Activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Share-based compensation arrangement by share-based payment award, award vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Counterparty Name [Axis] Counterparty Name [Axis] Liabilities and Stockholders’ Equity Liabilities and Equity [Abstract] All Award Types Award Type [Domain] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Number of Warrants (in shares) Class of Warrant or Right, Outstanding Supplemental cash flow information: Supplemental Cash Flow Information [Abstract] Expected life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Share price (in dollars per share) Share Price PEO Name PEO Name Number of patients receiving maximum dose Clinical Trial, Number of Patients Receiving Maximum Dose Clinical Trial, Number of Patients Receiving Maximum Dose 2024 2024 [Member] 2024 [Member] Accrued expenses Increase (Decrease) in Accrued Liabilities Restricted cash Restricted Cash Number of patients experiencing adverse effects Clinical Trial, Number of Patients Experiencing Adverse Effects Clinical Trial, Number of Patients Experiencing Adverse Effects Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Entity Tax Identification Number Entity Tax Identification Number Legal Entity [Axis] Legal Entity [Axis] Prefunded Warrants Prefunded Warrants [Member] Prefunded Warrants [Member] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Cash and cash equivalents and restricted cash, beginning of period Cash and cash equivalents and restricted cash, end of period Total cash and cash equivalents and restricted cash in the consolidated statements of cash flows Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Accounts payable Increase (Decrease) in Accounts Payable Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code ATM Agreement ATM Agreement [Member] ATM Agreement [Member] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Non-NEOs Non-NEOs [Member] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Organization and Nature of Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Equity method investment, ownership percentage Equity Method Investment, Ownership Percentage Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Remaining capacity under ATM agreement Remaining Capacity Under ATM Agreement Remaining capacity under ATM Agreement. Investment, Name [Domain] Investment, Name [Domain] Net loss per common share attributable to common stockholders - basic (in dollars per share) Earnings Per Share, Basic Total current assets Assets, Current Statistical Measurement [Axis] Statistical Measurement [Axis] Insider Trading Arrangements [Line Items] Cost of collaboration revenue Total cost of revenue Cost of Revenue Award Type [Axis] Award Type [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Equity Line of Credit Equity Line of Credit [Member] Equity Line of Credit [Member] Accumulated deficit Retained Earnings (Accumulated Deficit) Debt instrument, convertible, threshold trading days Debt Instrument, Convertible, Threshold Trading Days Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Common Stock Common Stock [Member] Internally Development Drug Projects Internally Development Drug Projects [Member] Internally Development Drug Projects [Member] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Statement [Table] Cover [Abstract] Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Percentage of total consideration Value of Equity Securities Received from Customer, Percentage of Total Consideration Value of Equity Securities Received from Customer, Percentage of Total Consideration Accrued annual license fee Accrued annual license fee Accrued annual license fee. Derivative Contract [Domain] Derivative Contract [Domain] Equity Awards Adjustments Equity Awards Adjustments [Member] Total liabilities and stockholders’ equity Liabilities and Equity Share-Based Payment Arrangement, Option Share-Based Payment Arrangement, Option [Member] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Plan Name [Axis] Plan Name [Axis] Tabular List, Table Tabular List [Table Text Block] Additional paid-in capital Additional Paid in Capital 2025 2025 [Member] 2025 [Member] 2023 2023 [Member] 2023 [Member] Name Awards Close in Time to MNPI Disclosures, Individual Name Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Aggregate Intrinsic Value, Outstanding at Beginning Aggregate Intrinsic Value, Outstanding at Ending Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Line of credit remaining borrowing capacity Line of Credit, Remaining Borrowing Capacity Line of credit remaining borrowing capacity. Forfeited / canceled (in share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period General and administrative General and Administrative Expense Sale of stock, price per share (in dollars per share) Sale of Stock, Price Per Share Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Series A Convertible Preferred stock, $0.00001 par value, 5,500,000 shares authorized; 73,449 shares issued and outstanding as of June 30, 2026 and December 31, 2025. Preferred Stock, Value, Issued George Washington University - Beta2-spectrin siRNA License Agreement George Washington University - Beta2-spectrin siRNA License Agreement [Member] George Washington University - Beta2-spectrin siRNA License Agreement [Member] Adjustment to Compensation: Adjustment to Compensation [Axis] Class of Stock [Domain] Class of Stock [Domain] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activity Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Credit Facility [Axis] Credit Facility [Axis] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Aggregate intrinsic value, Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Intrinsic Value Share based compensation arrangement by share based payment award options granted intrinsic value. Vested, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number 2022 Equity Incentive Plan Two Thousand Twenty Two Equity Incentive Plan [Member] 2022 Equity Incentive Plan [Member] Name Measure Name Income Taxes Income Tax Disclosure [Text Block] Accounts payable Accounts Payable, Current Pay vs Performance Disclosure [Line Items] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Additional Paid-in Capital Additional Paid-in Capital [Member] Entity Filer Category Entity Filer Category Expenses incurred in connection Expenses Incurred in Connection with ATM Sales and the Establishment of the ATM Facility Expenses incurred in connection with ATM sales and the establishment of the ATM facility. Name Trading Arrangement, Individual Name Share-based payment arrangement, nonvested award, excluding option, cost not yet recognized, amount Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Cash and cash equivalents Cash and Cash Equivalent Weighted average number of shares, restricted stock (in share) Weighted Average Number of Shares, Restricted Stock Company Selected Measure Amount Company Selected Measure Amount Vested, Weighted-Average Remaining Contractual Term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Entity Address, Address Line Two Entity Address, Address Line Two Stock, Class of Stock [Table] Stock, Class of Stock [Table] Current assets Assets, Current [Abstract] Non-PEO NEO Non-PEO NEO [Member] Entity Address, Address Line One Entity Address, Address Line One Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Other income Other Nonoperating Income Upfront license fee Upfront License Fee Upfront license fee. Award Timing Method Award Timing Method [Text Block] Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Payments on short term insurance financing Repayments of Other Short-Term Debt Initial term Collaborative Arrangement, Term Collaborative Arrangement, Term Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Expected volatility, Minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Net loss Net loss Net Income (Loss) Attributable to Parent Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] ATM expenses not yet paid ATM Expenses Not Yet Paid ATM expenses not yet paid. Statement [Table] Statement [Table] 2028 2028 [Member] 2028 [Member] Restatement Determination Date: Restatement Determination Date [Axis] Class of warrant or right, number of securities called by each warrant or right (in share) Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Interest income Investment Income, Interest Cash and Cash Equivalents, Restricted Cash, and Concentration of Credit Risk Cash and Cash Equivalents, Restricted Cash, and Concentration of Credit Risk [Policy Text Block] Cash And Cash Equivalents And Concentration Of Credit Risk [Policy Text Block] 2029 2029 [Member] 2029 [Member] Debt instrument, convertible, threshold consecutive trading days Debt Instrument, Convertible, Threshold Consecutive Trading Days Income from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Accrued revenue Accrued Revenue, Current Accrued Revenue, Current Revenue Revenues [Abstract] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block]